VYNE Therapeutics (NASDAQ:VYNE), Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for migraine and other central nervous system disorders. Headquartered in Malvern, Pennsylvania, VYNE leverages its proprietary V-Torque™ formulation and delivery technology to enhance the absorption and efficacy of existing active pharmaceutical ingredients. The company’s research and development efforts center on improving patient outcomes while minimizing systemic side effects typically associated with oral therapies.
VYNE’s lead product candidate, Qtrypta™ (zolmitriptan nasal spray), is designed for the acute treatment of migraine attacks in adults. Built on the company’s V-Torque platform, Qtrypta aims to offer rapid onset of action and greater bioavailability compared to currently available nasal formulations. In addition, VYNE markets ZTlido® (lidocaine topical system) for the management of post-herpetic neuralgia, a product licensed from scirepgane partners. ZTlido received U.S. Food and Drug Administration approval in 2018 and has since been distributed through a network of specialty and mail-order pharmacies.
Since its founding in 2015, VYNE has established strategic collaborations to support the clinical advancement and commercialization of its pipeline candidates. The company primarily serves the U.S. market and is preparing for a broader North American roll-out of Qtrypta pending regulatory approvals and market launch preparations. VYNE’s commercial team works closely with healthcare providers, including neurologists and pain specialists, to integrate new treatment options into current practice settings.
Leadership at VYNE Therapeutics is headed by President and Chief Executive Officer Robert Azelby, who brings over two decades of experience in specialty pharmaceuticals and commercialization. The executive team combines expertise in clinical development, regulatory affairs, and commercial operations, underscoring the company’s commitment to delivering innovative therapies for patients with unmet medical needs. VYNE continues to advance its pipeline through late-stage clinical studies while exploring additional indications for its V-Torque technology platform.
